Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Huadong Buys Asia Rights for Two Immune Therapies for $383 Million

publication date: Aug 22, 2024

Hangzhou’s Huadong Pharmaceutical acquired rights for two immune disease therapies from IMBiologics of South Korea in a $383 million agreement plus royalties. $8 million of the total are upfront payments. The two candidates are both antibodies: IMB-101 is a bispecific that targets both the autoimmune disease antibody OX40L and tumor necrosis factor (TNF); IMB-102 is a monospecific antibody IMB-102 that targets OX40L. Earlier this year, IMBiologics sold US rights to the pair in a $995 million deal with Navigator Medicines. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here